178 related articles for article (PubMed ID: 14755676)
21. The role of PC-SPES, selenium, and vitamin E in prostate cancer.
Das P; Kaplan I
Oncology (Williston Park); 2002 Mar; 16(3):285-91; discussion 291, 295-6, 299-300. PubMed ID: 15046388
[TBL] [Abstract][Full Text] [Related]
22. Current and future status of prostate cancer chemoprevention.
Fujimoto N; Nomura M; Matsumoto T
Expert Rev Anticancer Ther; 2006 Jan; 6(1):59-71. PubMed ID: 16375645
[TBL] [Abstract][Full Text] [Related]
23. Critical review of complementary therapies for prostate cancer.
Wilkinson S; Chodak GW
J Clin Oncol; 2003 Jun; 21(11):2199-210. PubMed ID: 12775747
[TBL] [Abstract][Full Text] [Related]
24. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer: chemoprevention update 2005.
Fleshner N; Al Azab R
Can J Urol; 2005 Jun; 12 Suppl 2():2-4. PubMed ID: 16018824
[TBL] [Abstract][Full Text] [Related]
27. Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial.
Klein EA
Recent Results Cancer Res; 2003; 163():212-25; discussion 264-6. PubMed ID: 12903856
[TBL] [Abstract][Full Text] [Related]
28. Prevention of lung cancer. The new millennium.
Kim ES; Hong WK; Khuri FR
Chest Surg Clin N Am; 2000 Nov; 10(4):663-90, v. PubMed ID: 11091919
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer prevention trial launched.
DeFrancesco L
Nat Med; 2001 Oct; 7(10):1076. PubMed ID: 11590411
[No Abstract] [Full Text] [Related]
30. The selenium and vitamin E cancer prevention trial.
Klein EA; Lippman SM; Thompson IM; Goodman PJ; Albanes D; Taylor PR; Coltman C
World J Urol; 2003 May; 21(1):21-7. PubMed ID: 12756490
[TBL] [Abstract][Full Text] [Related]
31. An update on chemoprevention strategies in prostate cancer for 2006.
Neill MG; Fleshner NE
Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
[TBL] [Abstract][Full Text] [Related]
32. RE: Lessons from the selenium and vitamin E cancer prevention trial (SELECT).
Schrauzer GN
Crit Rev Biotechnol; 2009; 29(2):81. PubMed ID: 19514891
[No Abstract] [Full Text] [Related]
33. Prostate cancer prevention: past, present, and future.
Fleshner N; Zlotta AR
Cancer; 2007 Nov; 110(9):1889-99. PubMed ID: 17893870
[TBL] [Abstract][Full Text] [Related]
34. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
Kim J; Sun P; Lam YW; Troncoso P; Sabichi AL; Babaian RJ; Pisters LL; Pettaway CA; Wood CG; Lippman SM; McDonnell TJ; Lieberman R; Logothetis C; Ho SM
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1697-702. PubMed ID: 16030104
[TBL] [Abstract][Full Text] [Related]
35. Future directions in the prevention of prostate cancer.
Thompson IM; Cabang AB; Wargovich MJ
Nat Rev Clin Oncol; 2014 Jan; 11(1):49-60. PubMed ID: 24281061
[TBL] [Abstract][Full Text] [Related]
36. Current issues of selenium in cancer chemoprevention.
Jung HJ; Seo YR
Biofactors; 2010; 36(2):153-8. PubMed ID: 20333751
[TBL] [Abstract][Full Text] [Related]
37. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
38. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention.
Shirai T
Pathol Int; 2008 Jan; 58(1):1-16. PubMed ID: 18067635
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: a serious disease suitable for prevention.
Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
[TBL] [Abstract][Full Text] [Related]
40. Phase III prostate cancer prevention trials: are the costs justified?
Thompson IM; Tangen CM; Klein EA; Lippman SM
J Clin Oncol; 2005 Nov; 23(32):8161-4. PubMed ID: 16278467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
